All News

The Company announces that it has raised £600,000 from the issue of 120,000,000 new ordinary shares of 0.04p each ("Ordinary Shares") at a price of 0.5p per share, by way of a placing through WH Ireland Limited (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 12 April 2011. Read...

Read More

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the AACR 102nd Annual Meeting 2011, taking place in the Orange County Convention Center, Orlando, Florida on 2-6 April 2011.  Dr Eric Fernandez, Project Leader at Physiomics, will present on a validation of our Virtual Tumour platform, which was completed in collaboration with Eli Lilly...

Read More

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that positive results have been generated in a pre-clinical in-vivo study into breast cancer based on the Company’s “Virtual Tumour”  model predictions. The directors believe these results provide further validation as to the predictive capability of the Company’s technology. Read more...

Read More

Physiomics (AIM: PYC), the Oxford, UK, based systems biology company, is pleased to announce the appointment of Dr Mark Chadwick as Chief Executive Officer of the Company. As a Director of the Company he will join the main Board and the Remuneration Committee. Read more ...

Read More

Physiomics (AIM: PYC), the Oxford, UK based systems biology company,is pleased to announce that the Company together with Green Biologics Limited (GBL) and North Energy Associates Limited has been awarded a total grant for £268,000 from the Carbon Trust for a project to demonstrate an Advanced Fermentation Process for Butanol. Read more...

Read More

Physiomics have validated their Virtual Tumour model in single-blind experiments with a major pharma company. The model successfully predicted the outcome of two drug combination xenograft studies. The results are presented in an article for Innovations in Pharmaceutical Technology (June issue)....

Read More

Physiomics “fabrique“ des tumeurs virtuelles. (In French) "De la biologie cellulaire aux mathématiques appliqués, Physiomics construit ses modèles pour répondre à des problématiques biologiques. Essentiellement descriptifs à l’origine, ceux-ci deviennent de plus en plus prédictifs". (From cell biology to applied mathematics, Physiomics builds models to answer biological questions. Although such models were initially illustrative, they have become more and more predictive.) Features an interview of Dr...

Read More

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, and Sareum Holdings plc (AIM: SAR) are pleased to announce that they have signed an agreement in which Physiomics provides in silico simulations to support Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT)....

Read More

The Company announces that it has completed a placing, through WH Ireland Limited, to raise £782,500 from the issue of 195,625,000 new ordinary shares of 0.04p each (“Ordinary Shares”) at a price of 0.4p per share (the “Placing”). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 4 December 2009....

Read More